Publications by authors named "Yogamba M Shivakumar"
Background: Although phenytoin's potential benefits in wound healing, pain relief, and infection control across various wound types have been previously reported, its use in wound care remains limited.
Objective: To conduct a comprehensive review to assess the efficacy of topical phenytoin compared with standard and alternative treatments for different wound types.
Materials And Methods: The authors last searched Cochrane Library, PubMed, PubMed Central, and MEDLINE in June 2023.
Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug widely used as part of antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV-1) infection. Negative effects of tenofovir include impaired kidney function, especially with long-term use. In studies conducted among HIV-positive individuals, we found evidence of extensive kidney damage associated with TDF use.
View Article and Find Full Text PDFThe Helicobacter pylori infection is a significant issue in global health as it is associated with a range of gastrointestinal disorders and an elevated likelihood of developing stomach cancer. The declining efficacy of standard triple therapy (TT) as the recommended treatment can be attributed to the emergence of drug-resistant strains. Sequential therapy (ST) has been recognized as an alternative approach, wherein a combination of proton-pump inhibitor (PPI) and amoxicillin is administered for the initial five days, followed by a combination of PPI, clarithromycin, and metronidazole for the subsequent five days.
View Article and Find Full Text PDFArticle Synopsis
- Amyloid-ß plaques and Neurofibrillary tangles are key features of Alzheimer's disease, motivating research into potential treatments like Anti-Aß monoclonal antibodies and angiotensin-receptor blockers (ARBs).
- This analysis evaluates existing evidence from studies on various monoclonal antibodies (Aducanumab, Lecanemab, Donanemab, and Solanezumab) and ARBs, emphasizing their effects on managing Alzheimer's.
- Results indicate that monoclonal antibodies are generally more effective than ARBs for reducing plaques, particularly Aducanumab and Lecanemab, while ARBs are considered a safer option; however, further long-term studies are necessary for comprehensive safety and efficacy insights.